This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Schapiro, R. T. Search for Related Content PubMed PubMed Citation Articles by Schapiro, R. T. Social Bookmarking                         What's this?

Pharmacologic Options for the Management of Multiple Sclerosis Symptoms

Fairview Multiple Sclerosis Center, Minneapolis, Minnesota, schap003{at}maroon.tc.umn.edu

Multiple sclerosis (MS) is a disease with a wide-ranging impact on physical functioning. Although pharmacotherapy plays an indispensable role in the management of MS symptoms, optimal disease management requires a multidisciplinary approach that combines medication, rehabilitation, and patient education. Successful control of symptoms is critical to quality of life for MS patients. Immunomodulating drugs provide a means of controlling the underlying disease process, but they are not a cure. This places responsibility on health care providers to control a patient’s MS-related symptoms to limit disability and delay impairment in the activities of daily living. Owing to the importance of symptom control, comprehensive patient evaluations should be performed at regular intervals to determine the extent of neurological damage and disease progression and to address changing patient needs. The goal of interventions should be not only to treat the primary and secondary symptoms of MS but also to provide access to the psychosocial support that will help MS patients and their families continue to cope as disease status changes.

Key Words: Multiple sclerosis • Primary symptoms • Secondary symptoms

Neurorehabilitation and Neural Repair, Vol. 16, No. 3, 223-231 (2002)
DOI: 10.1177/154596802401105162


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. M. Weisbrot, A. B. Ettinger, K. D. Gadow, A. L. Belman, W. S. MacAllister, M. Milazzo, M. L. Reed, D. Serrano, and L. B. Krupp Psychiatric Comorbidity in Pediatric Patients With Demyelinating Disorders J Child Neurol, February 1, 2010; 25(2): 192 - 202. [Abstract] [PDF]

				S. J. Page, P. Levine, and J. C. Khoury Modified Constraint-Induced Therapy Combined With Mental Practice: Thinking Through Better Motor Outcomes Stroke, February 1, 2009; 40(2): 551 - 554. [Abstract] [Full Text] [PDF]

				S. Page and P. Levine Author Response Physical Therapy, May 1, 2008; 88(5): 684 - 688. [Full Text] [PDF]

				S. J Page, P. Levine, A. Leonard, J. P Szaflarski, and B. M Kissela Modified Constraint-Induced Therapy in Chronic Stroke: Results of a Single-Blinded Randomized Controlled Trial Physical Therapy, March 1, 2008; 88(3): 333 - 340. [Abstract] [Full Text] [PDF]

				S. J. Page, C.-y. Wu, and K.-c. Lin Letter to the Editor Neurorehabil Neural Repair, December 1, 2007; 21(6): 574 - 575. [PDF]

				S. J Page and P. Levine Modified Constraint-Induced Therapy in Patients With Chronic Stroke Exhibiting Minimal Movement Ability in the Affected Arm Physical Therapy, July 1, 2007; 87(7): 872 - 878. [Abstract] [Full Text] [PDF]